Last updated: September 28, 2026
Infliximab has shifted from a high-growth branded biologic into a mature, multisource market. Remicade sales have declined sharply since biosimilar entry, while Inflectra, Renflexis, Avsola, and other infliximab products have expanded access through lower prices, payer substitution, and hospital purchasing. The reference product retains substantial revenue because of physician familiarity and entrenched use in inflammatory bowel disease, rheumatoid arthritis, psoriasis, and related conditions, but the long-term market is governed by biosimilar competition rather than originator exclusivity.
What is the current infliximab market structure?
Infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha, or TNF-alpha. The reference product is Remicade, developed by Centocor and commercialized by Johnson & Johnson through Janssen. Merck has held commercialization rights in several non-U.S. markets.
The product is administered by intravenous infusion. That delivery model creates a different competitive environment from self-injected TNF inhibitors such as adalimumab and etanercept. Infusion centers, hospital formularies, buy-and-bill economics, switching protocols, and contracting arrangements influence product selection.
| Product |
Company or sponsor |
U.S. FDA status |
Principal market position |
| Remicade |
Janssen / Johnson & Johnson |
Reference biologic, approved 1998 |
Originator product with declining share |
| Inflectra |
Celltrion; commercialized in the U.S. by Pfizer |
Biosimilar, approved 2016 |
First U.S. infliximab biosimilar |
| Renflexis |
Samsung Bioepis; commercialized by Organon |
Biosimilar, approved 2017 |
Hospital and payer-focused competitor |
| Ixifi |
Pfizer |
Biosimilar, approved 2017 |
Limited U.S. commercial impact |
| Avsola |
Amgen |
Biosimilar, approved 2019 |
Major U.S. commercial competitor |
| Flixabi |
Samsung Bioepis / Biogen in Europe |
Biosimilar |
European infliximab biosimilar |
| Remsima |
Celltrion |
Biosimilar in Europe and other markets |
Broad international presence |
The FDA lists infliximab biosimilars in the Purple Book rather than the Orange Book. The Orange Book generally covers small-molecule drugs and does not function as the principal patent listing system for biologics.
How large is the infliximab market?
The global infliximab market is difficult to measure because company reporting separates reference-product sales from biosimilar sales and often combines products by geography or therapeutic franchise. Public company filings provide the most reliable view of originator revenue erosion.
Janssen’s Remicade revenue fell from multibillion-dollar peak levels to approximately $2 billion annually in the early 2020s. The decline reflects biosimilar uptake, net-price reductions, contracting pressure, and physician switching.
| Period |
Remicade commercial trajectory |
Primary driver |
| 2010-2015 |
Peak and late-maturity growth |
Broad label expansion and limited direct competition |
| 2016-2017 |
Beginning of U.S. biosimilar pressure |
Inflectra and Renflexis approvals and launches |
| 2018-2020 |
Rapid revenue erosion |
Multiple biosimilar competitors and payer controls |
| 2021-2023 |
Mature decline |
Price compression, switching, and loss of preferred formulary status |
| 2024 onward |
Low-growth or declining originator market |
Multisource competition and physician familiarity with biosimilars |
Janssen reported Remicade sales of approximately $2.0 billion in 2023, compared with substantially higher revenue before U.S. biosimilar commercialization. Exact totals vary by reporting period and currency translation. Pfizer, Organon, Amgen, Celltrion, and Samsung Bioepis do not disclose a single consolidated global infliximab revenue figure that permits a clean market-share calculation. [1-5]
The commercial value has therefore migrated from the originator to a broader infliximab market. Biosimilar manufacturers compete for volume through:
- Lower acquisition cost
- Hospital and integrated-delivery-network contracts
- Rebate arrangements with pharmacy benefit managers
- Infusion-center economics
- Patient-support services
- Switching studies and physician education
- Regional tender awards outside the United States
When did infliximab lose market exclusivity?
Infliximab lost practical market exclusivity in stages rather than on one global date.
The FDA approved Remicade in 1998. The United States provided 12 years of reference-product biologic exclusivity under the Biologics Price Competition and Innovation Act. That period expired in 2010, but patents, regulatory development time, litigation, and settlement agreements delayed commercial biosimilar entry.
The first U.S. infliximab biosimilar, Inflectra, received FDA approval in April 2016 and launched in the United States in 2016. Renflexis followed in 2017, Avsola in 2019, and additional products became available in subsequent years.
| Event |
Date |
Commercial significance |
| Remicade FDA approval |
1998 |
Reference-product launch |
| BPCIA reference-product exclusivity |
2010 expiration |
Regulatory exclusivity ended before commercial entry |
| First European infliximab biosimilar approvals |
2013 |
Early European price competition |
| Inflectra FDA approval |
April 2016 |
First U.S. biosimilar approval |
| Renflexis FDA approval |
May 2017 |
Expanded U.S. competition |
| Avsola FDA approval |
December 2019 |
Added a large U.S. manufacturer |
| U.S. Medicare Part B biosimilar payment reforms |
2020-2023 |
Improved reimbursement incentives for some products |
European markets experienced biosimilar competition earlier than the United States. National tender systems and hospital procurement accelerated switching in countries such as Norway, Denmark and the United Kingdom. U.S. adoption was slower because of fragmented reimbursement, provider concerns about automatic substitution, and originator contracting.
What patents protect infliximab and Remicade?
The principal Remicade composition-of-matter patent was U.S. Patent No. 6,015,557, covering antibodies that bind TNF-alpha, including infliximab-related subject matter. The patent expired in the United States in 2018 after patent-term adjustment. Other patents covered antibody production, formulations, dosing methods, and manufacturing-related subject matter.
| Patent category |
Protection scope |
Commercial status |
| Antibody composition |
Anti-TNF antibody structures and binding characteristics |
Core protection expired |
| Cell lines and production |
Recombinant production systems and manufacturing methods |
Scope varies by jurisdiction and claim construction |
| Formulation |
Stability, concentration, excipients, and dosage forms |
Some claims extended beyond core composition patents |
| Method of treatment |
Use in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis and other diseases |
Patent terms and enforceability vary |
| Dosing regimen |
Induction, maintenance, escalation, and retreatment protocols |
Usually narrower and more vulnerable to design-around |
| Manufacturing process |
Cell culture, purification, and quality-control methods |
Can create execution barriers without blocking the entire market |
Unlike a small-molecule product, a biologic does not depend on a single Orange Book patent listing for commercial protection. Biologic patent disputes typically involve the BPCIA patent-exchange process, district-court litigation, declaratory-judgment actions, and patent settlements.
The practical barrier to entry is now less the expired core antibody patent than the ability to develop a product with comparable analytical characteristics, clinical support, manufacturing capacity, and payer access.
What is the Orange Book and Purple Book status of infliximab?
Remicade is regulated as a biologic under a biologics license application, or BLA, rather than as a conventional new drug application. The relevant FDA reference is the Purple Book.
The FDA-approved infliximab biosimilars include products with biosimilarity to Remicade. A biosimilar designation does not automatically grant interchangeability. Interchangeability is a separate FDA designation that can support pharmacy-level substitution under state law, although infliximab is primarily administered in clinical settings.
The central regulatory distinctions are:
| Regulatory issue |
Infliximab implication |
| Reference product |
Remicade |
| Regulatory pathway |
351(k) biosimilar pathway |
| Primary FDA reference |
Purple Book |
| Automatic substitution |
Depends on FDA interchangeability and state law |
| Infusion administration |
Provider and institutional control remains important |
| Extrapolation |
Biosimilar approval can cover multiple indications without separate trials in every indication |
| Post-market monitoring |
Immunogenicity, infusion reactions, and switching data remain commercially relevant |
Inflectra was approved as biosimilar to Remicade for multiple indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. Avsola and Renflexis received similarly broad indications through extrapolation. [6-9]
Which companies are challenging Remicade?
The most important commercial challengers are Pfizer, Organon, Amgen, Celltrion and Samsung Bioepis.
Pfizer and Celltrion
Pfizer commercializes Inflectra in the United States under an agreement with Celltrion. Inflectra benefited from being the first U.S.-approved infliximab biosimilar and from Pfizer’s established hospital and specialty distribution infrastructure.
Celltrion also commercializes Remsima in international markets. Its strategy has included direct biosimilar commercialization, partnerships, and expansion into subcutaneous infliximab products in selected jurisdictions.
Organon and Samsung Bioepis
Organon markets Renflexis in the United States. The product targets hospital systems and payers that prioritize lower acquisition cost and predictable supply. Samsung Bioepis has also supplied Flixabi in Europe through commercial partnerships.
Amgen
Amgen markets Avsola in the United States. Its competitive strengths include national payer relationships, manufacturing scale, and experience with large biologic franchises. Avsola gives Amgen a direct position in a mature TNF inhibitor market.
Janssen
Janssen remains the originator company. Its defense has relied on brand equity, clinical familiarity, contracting, patient-support programs, and continued use in patients stable on Remicade. The company has shifted growth emphasis toward newer immunology medicines, including Stelara and Tremfya, rather than relying on infliximab for franchise expansion.
How strong is the infliximab patent estate?
The infliximab patent estate is weak as a blocking estate for new U.S. competition but remains relevant to litigation risk in specific manufacturing and formulation areas.
The core antibody patent has expired. Remaining patents generally have one or more limitations:
- They cover a narrow formulation or process.
- They apply only in selected jurisdictions.
- They may be avoided through alternative manufacturing methods.
- They may not prevent approval of a biosimilar if the biosimilar sponsor certifies non-infringement or invalidity.
- They may support settlement leverage without preserving broad market exclusivity.
Patent strength is therefore better described as product-specific than molecule-wide. A biosimilar manufacturer can obtain regulatory approval while still facing commercial or legal exposure based on process patents. The main risks concern manufacturing disclosure, claim scope, freedom-to-operate analysis, and the timing of launch.
What patent litigation and settlement agreements affect infliximab?
Infliximab biosimilar competition has involved the BPCIA patent framework and negotiated launch arrangements. The commercial pattern has been similar to other biologics: biosimilar approval may precede the commercial launch, with the parties reaching a settlement that defines an entry date or resolves selected patent claims.
The principal litigation risks are:
- Patent infringement claims involving cell culture or purification processes
- Formulation patent assertions
- Disputes over patent-exchange compliance
- Declaratory-judgment actions
- Launch-at-risk exposure
- Contracting and antitrust scrutiny related to originator rebates
- Product-liability and immunogenicity claims after switching
Publicly available litigation records do not establish a single remaining patent barrier that blocks the U.S. infliximab market. The current legal environment is characterized by execution risk and localized patent disputes rather than broad composition-of-matter exclusivity.
What formulations and delivery systems are protected?
The commercial reference product is an intravenous formulation supplied for infusion after reconstitution. Formulation protection may address excipient composition, concentration, stability, lyophilization, aggregation control, and storage.
A major technical development is subcutaneous infliximab. Celltrion’s Remsima SC has been approved in Europe and other jurisdictions as a subcutaneous formulation of infliximab. It changes the competitive profile by reducing reliance on infusion centers and allowing maintenance administration outside the infusion setting.
| Delivery system |
Commercial effect |
| Intravenous infusion |
Supports provider administration and buy-and-bill economics |
| Subcutaneous injection |
Expands home-administration potential and convenience |
| Lyophilized vial |
Requires reconstitution and controlled preparation |
| Pre-filled or ready-to-use systems |
Can reduce administration burden but require device and stability development |
Subcutaneous infliximab may protect differentiated pricing in markets where convenience and healthcare-resource savings matter. It also creates additional patent and regulatory layers involving formulation, device design, dosing, and administration method.
What is the revenue exposure for manufacturers and investors?
For Janssen, Remicade revenue is now a declining contribution to the immunology portfolio. The product remains commercially meaningful because of its installed patient base, but its strategic value is lower than that of newer medicines with stronger exclusivity.
For biosimilar manufacturers, infliximab offers a large but price-sensitive market. Revenue depends on volume capture rather than premium pricing. The strongest commercial positions are likely to belong to companies that combine:
- Reliable supply
- Low cost of goods
- National payer access
- Hospital contracting
- Physician confidence
- Patient-support infrastructure
- Multiple biologic products in the same account
The market has a high risk of gross-to-net erosion. A manufacturer can gain units while losing revenue per unit if contracting requires steep discounts. Hospital tenders can also produce rapid share changes and limited visibility into realized net prices.
How does infliximab compare with adalimumab and etanercept?
Infliximab has earlier biosimilar competition than adalimumab in the United States but a more complex administration model.
| Factor |
Infliximab |
Adalimumab |
Etanercept |
| Administration |
Primarily intravenous; subcutaneous versions in some markets |
Subcutaneous |
Subcutaneous |
| Originator |
Remicade |
Humira |
Enbrel |
| U.S. biosimilar timing |
2016 first approval |
2023 first commercial launches |
Limited U.S. biosimilar availability |
| Switching control |
Infusion provider and payer |
Pharmacy and payer channels increasingly important |
Pharmacy and payer channels |
| Main commercial barrier |
Infusion logistics and contracting |
Formulary concentration and rebate structures |
Patent and regulatory barriers |
| Competitive price pressure |
High |
High after 2023 |
Lower where biosimilar competition is limited |
Infliximab’s infusion model can slow switching in stable patients but can also give hospitals stronger control over product selection. Adalimumab’s pharmacy-based distribution allows more direct payer substitution, while infliximab decisions are often made by health systems, infusion providers, and specialists.
What generic or biosimilar launch scenarios exist?
Three scenarios dominate the market.
Continued originator erosion
Remicade retains a loyal installed base, but new starts increasingly favor lower-cost biosimilars. Originator revenue continues to decline through price concessions and reduced share.
Concentrated biosimilar market
A small number of manufacturers secure preferred contracts. Volume shifts among Inflectra, Renflexis and Avsola, while smaller products remain approved but commercially marginal.
Differentiated subcutaneous growth
Subcutaneous infliximab captures patients who value home administration or reduced infusion-center use. This could create a higher-value segment, although payers may demand discounts relative to intravenous products.
The most likely market outcome is a concentrated biosimilar market with ongoing price competition and a differentiated subcutaneous segment.
What geographic markets offer the strongest infliximab growth?
Europe has the most mature biosimilar environment. Hospital tenders, national procurement, and physician switching programs have produced substantial biosimilar uptake. The United States remains commercially important because of market size and reimbursement, but adoption is slower and more dependent on contracting.
Emerging markets offer volume growth but usually lower realized prices. Local manufacturing, government procurement, and registration requirements can influence market access. In countries with weak biologic interchangeability rules, physician prescribing and hospital procurement remain decisive.
Japan and selected Asian markets have developed their own regulatory and reimbursement dynamics. Celltrion, Samsung Bioepis, Pfizer, Amgen and regional manufacturers compete through local partnerships and tender access.
Key Takeaways
- Remicade has moved from a protected biologic franchise into a mature multisource market.
- The core U.S. patent estate no longer blocks broad infliximab competition.
- The FDA approved the first U.S. infliximab biosimilar, Inflectra, in 2016.
- Renflexis, Avsola and other biosimilars have increased price and formulary pressure.
- Janssen Remicade revenue has declined from peak levels to roughly $2 billion annually in the early 2020s.
- The Purple Book, not the Orange Book, is the principal FDA reference for infliximab biologic competition.
- Manufacturing, formulation and process patents remain relevant but are narrower than the expired core antibody protection.
- Hospital contracting and infusion economics are more important than pharmacy substitution for many U.S. patients.
- Subcutaneous infliximab is the main potential product-differentiation strategy.
- The market outlook favors lower prices, concentrated biosimilar share and continued originator revenue erosion.
FAQs About Infliximab Market Exclusivity and Competition
When did the first infliximab biosimilar launch in the United States?
Inflectra launched in the United States in 2016 after FDA approval in April of that year.
Is Remicade still protected by patents?
The principal composition patent has expired in the United States. Some formulation, manufacturing and method-of-use patents may have had later expiration dates or remain relevant in particular jurisdictions.
Does infliximab have an Orange Book listing?
No conventional Orange Book listing controls infliximab biosimilar competition. Remicade is regulated under a BLA, and the FDA Purple Book identifies biosimilar products.
Which infliximab biosimilar has the strongest commercial position?
Inflectra has the advantage of first U.S. entry and Pfizer’s commercial infrastructure. Avsola and Renflexis remain important competitors, particularly in payer and hospital contracting.
Can patients be automatically switched from Remicade to an infliximab biosimilar?
Automatic substitution depends on FDA interchangeability status, state law, payer policy and provider practice. In many clinical settings, switching is managed by the treating physician, infusion provider or health system.
References
-
Johnson & Johnson. (2024). Annual report 2023. Johnson & Johnson.
-
U.S. Food and Drug Administration. (2016). FDA approves Inflectra, a biosimilar to Remicade. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2017). FDA approves Renflexis, a biosimilar to Remicade. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2019). FDA approves Avsola, a biosimilar to Remicade. U.S. Department of Health and Human Services.
-
Pfizer Inc. (2024). Annual report 2023. Pfizer Inc.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
European Medicines Agency. (2013). Remsima: EPAR. European Medicines Agency.
-
European Medicines Agency. (2019). Remsima and Flixabi product information. European Medicines Agency.
-
U.S. Food and Drug Administration. (2024). Biosimilar product information. U.S. Department of Health and Human Services.
-
U.S. Patent No. 6,015,557. (2000). Chimeric antibodies to human tumor necrosis factor alpha. United States Patent and Trademark Office.
